Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02175771 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 758
- Enrollment target
NCT02175771 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 758 participants.
The verdict
NCT02175771, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 758 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the long-term safety of fluticasone propionate (Fp) inhalation powder in 2 strengths and fluticasone propionate/salmeterol inhalation (FS) powder in 2 strengths when administered with the Teva multidose dry powder inhaler (MDPI) device over 26 weeks in patients with persistent asthma.
Interventions
- DRUG ADVAIR DISKUS
- DRUG Fp MDPI
- DRUG FS MDPI
- DRUG FLOVENT HFA
- DRUG albuterol/salbutamol HFA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 758 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02175771
The ClinicalTrials.gov registry entry for NCT02175771 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 758 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ADVAIR DISKUS is the first listed.
NCT02175771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02175771 about?
NCT02175771 is a clinical study titled "Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma". The primary objective of the study is to evaluate the long-term safety of fluticasone propionate (Fp) inhalation powder in 2 strengths and fluticasone propionate/salmeterol inhalation (FS) powder in 2 strengths when administered with the Teva multidose dry powder inhaler (MDPI) device over 26 weeks ...
What is the current status of trial NCT02175771?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 758 participants. The study started on 2014-07. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02175771?
The interventions under investigation include: ADVAIR DISKUS (DRUG), Fp MDPI (DRUG), FS MDPI (DRUG), FLOVENT HFA (DRUG), albuterol/salbutamol HFA (DRUG).
Who is sponsoring clinical trial NCT02175771?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.